Updated on: 23 January 2024

Roles in: Infectious Diseases Group

1. In the past 36 months have you accepted the following from a commercial organisation with a financial interest in the broad topic area of the Group/Unit?

a) Support for attending meetings, including sabbaticals and study tours (this covers travel, accommodation and/or hospitality)?
No

b) Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events?
No

c) Fees for organising education?
No

d) Grants and contracts?
No

e) Funds for a member of staff?
No

f) Fees for consulting?
No

g) Royalty or licences payments?
No

h) Payment for expert testimony?
No

i) Payment for a fellowship?
No

j) Payment for participation on a Data Safety Monitoring Board, Advisory Board, or Guideline Panel?
No

k) Payment for a leadership or other fiduciary role in other board, society, committee, or advocacy group?
No

2. In the past 36 months have you, your spouse/partner or an immediate family member been employed by or do you or they own a commercial organization with a financial interest in the broad topic area of the Group/Unit?
No

3. Do you own stocks or shares in a commercial organization with a financial interest in the broad topic area of the Group/Unit?
No

4. Do you hold any patents (planned, issued or pending) for products relevant to the broad topic area of the Group/Unit?
No

5. Do you have any other competing interests (financial or non-financial)?
Yes - The University of Liverpool is a partner in the UNITE4TB consortium a public-private partnership supporting an international clinical trials platform in tuberculosis funded by EU-IMI that includes four pharmaceutical partners (GSK, Janssen, Otsuka and Evotech). However, all industrial contributions to the consortium are in-kind and neither I, my research group institution receive any funding from industry through this consortium. The University of Liverpool is also a partner without budget in the PanACEA consortium, a clinical trials platform supported by the EU European and Developing Countries Clinical Trials Partnership. Though this consortium has involved interactions with commercial partners (Qurient, Sequella) neither I, my research group, institution nor the clinical trial site that I support in Blantyre, Malawi, receive any funding from industry through this consortium. I have provided pro bono advice to advisory boards convened by GSK and Janssen for which I have received no payment or benefit, direct or otherwise (honorarium, expenses, hospitality). I am an collaborator on a grant from ViiV healthcare to my institution supporting a drug-drug interaction study of dolutegravir and high dose rifampicin but I do not receive any salary or other direct financial benefit from the project.